retatrutide triple agonist obesity New drugs are coming, including the 'triple agonist' (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of glp 1 average weight Weight Loss Program type:Semaglutide GLP-1 iron

retatrutide triple agonist obesity New drugs are coming, including the 'triple agonist' (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of glp 1 average weight Weight Loss Program type:Semaglutide GLP-1 iron

glp 1 average weight loss per week Study Shows Real World GLP-1 Results Less Than Trial Results When Doses are Lower : r/Zepbound Weight Loss Injections — MesoHealth –

Diabetes Care 21 , 1414–1431 (1998)

iron

Weight Loss Program type:Semaglutide GLP-1

Gallup’s research found a general alignment between GLP-1 usage and falling obesity rates across most age groups, with one notable exception: adults aged 65 and over, for whom reported effectiveness of the drugs is lower